PMID- 35622820
OWN - NLM
STAT- MEDLINE
DCOM- 20220531
LR  - 20220716
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 5
DP  - 2022
TI  - Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A 
      structural equation model (SEM) analysis.
PG  - e0269169
LID - 10.1371/journal.pone.0269169 [doi]
LID - e0269169
AB  - Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin's lymphoma of 
      increasing prevalence in Japan. However, patients with relapsed or refractory 
      disease to first line treatment (rrDLBCL) have been found to shoulder greater 
      economic burden and have poor survival with subsequent lines of therapy. The 
      relative impact of individual patient attributes on total medical cost among 
      patients with rrDLBCL receiving second or third line (2L/3L) therapy was 
      assessed. Structural equation modelling was used to identify potential cost 
      drivers of total medical costs incurred by treatment and procedures in a Japanese 
      retrospective claims database. From the database, rrDLBCL patients on 2L or 3L of 
      treatment were grouped into respective cohorts. The mean [median] (SD) total 
      medical cost of care for the 2L cohort was 73,296.40 [58,223.11] (58,409.79) US 
      dollars (USD) and 75,238.35 [60,477.31] (59,583.66) USD for the 3L cohort. The 
      largest total effect on medical cost in both cohorts was length of hospital stay 
      (LOS) (beta: 0.750 [95%CI: 0.728, 0.772] vs beta: 0.762 [95%CI: 0.729, 0.794]). Length 
      of hospital stay and potential heart disease complications due to line of 
      treatment were the primary drivers of total cost for patients who had received at 
      least 2L or 3L therapy for rrDLBCL.
FAU - Tsutsue, Saaya
AU  - Tsutsue S
AUID- ORCID: 0000-0002-8412-8778
AD  - Celgene K.K., a Bristol Myers Squibb Company, Tokyo, Japan.
FAU - Makita, Shinichi
AU  - Makita S
AUID- ORCID: 0000-0001-6609-8088
AD  - National Cancer Center Hospital, Tokyo, Japan.
FAU - Yi, Jingbo
AU  - Yi J
AD  - Syneos Health, Tokyo, Japan.
FAU - Crawford, Bruce
AU  - Crawford B
AD  - Syneos Health, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220527
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - *Antineoplastic Combined Chemotherapy Protocols
MH  - Humans
MH  - Japan/epidemiology
MH  - Length of Stay
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - Retrospective Studies
PMC - PMC9140275
COIS- Saaya Tsutsue is current employee of Celgene KK., a BMS company. B Crawford and J 
      Yi are current employees of Syneos Health Japan. S Makita has received honoraria 
      from: Celgene/BMS, Chugai, CSL Behring, Eisai, Novartis, SymBio, and Takeda 
      outside of this work. S Tsutsue, J Yi and B Crawford have no other relevant 
      affiliations or financial involvement with any organization or entity with a 
      financial interest in or financial conflict with the subject matter or materials 
      discussed in the manuscript apart from those disclosed. There are no patents, 
      products in development, or marketed products to declare for the target regimens 
      of this study. This does not alter our adherence to all PLOS ONE policies on 
      sharing data and materials.
EDAT- 2022/05/28 06:00
MHDA- 2022/06/01 06:00
PMCR- 2022/05/27
CRDT- 2022/05/27 13:34
PHST- 2021/05/24 00:00 [received]
PHST- 2022/05/16 00:00 [accepted]
PHST- 2022/05/27 13:34 [entrez]
PHST- 2022/05/28 06:00 [pubmed]
PHST- 2022/06/01 06:00 [medline]
PHST- 2022/05/27 00:00 [pmc-release]
AID - PONE-D-21-17013 [pii]
AID - 10.1371/journal.pone.0269169 [doi]
PST - epublish
SO  - PLoS One. 2022 May 27;17(5):e0269169. doi: 10.1371/journal.pone.0269169. 
      eCollection 2022.